![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Celltrion’s COVID-19 Antiviral Shows Positive Results in Pre-Clinical Studies
Celltrion’s COVID-19 Antiviral Shows Positive Results in Pre-Clinical Studies
![Positive Results](https://www.fdanews.com/ext/resources/test/Drug-Images4/Postitive-Results.gif?t=1623701844&width=430)
Celltrion’s investigational COVID-19 antiviral antibody has shown a 100-fold reduction in viral load in a pre-clinical study.
The trial assessed the efficacy of two dosage amounts. Both dosage groups saw inflammation return to normal within six days and a shortened recovery time.
The company is now conducting additional efficacy and toxicity testing in pre-clinical trials and plans to begin human trials next month.
Upcoming Events
-
18Jul
-
21Oct